This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton's Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions.

In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). - Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. - Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In this issue of Hematology/Oncology Clinics, guest editor David A. Reardon︎ brings his considerable expertise to the topic of Central Nervous System Malignancies. Top experts in the field cover key topics such as CNS Metastases, Leptomeningeal Disease, Neurofibromatoses, Imaging Advances for CNS Tumors, and more. - Contains 16 relevant, practice-oriented topics including CNS Tumor Classification: An Update on the Integration of Tumor Genetics; Etiology and Epidemiology of CNS Tumors; The Evolving Role of Neurosurgical Intervention for CNS Tumor ; Update on Radiation Therapy for CNS Tumors; and more. - Provides in-depth clinical reviews on CNS Malignancies, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In this issue of Hematology/Oncology Clinics, guest editors Drs. Jorge J. Castillo, Prashant Kapoor, and Shayna Sarosiek bring their considerable expertise to the topic of Waldenström Macroglobulinemia. Top experts in the field provide a focused update on the biology, diagnosis and management, and novel therapies for patients with Waldenström macroglobulinemia, a rare blood cell cancer characterized by an excess of abnormal white blood cells in the bone marrow. - Contains 14 practice-oriented topics including clinical implications of genomic profile in Waldenström macroglobulinemia; chemoimmunotherapy regimens in the frontline management of Waldenström macroglobulinemia; management of relapsed or refractory Waldenström macroglobulinemia; evaluation and management of aggressive transformation in Waldenström macroglobulinemia; management of Waldenström macroglobulinemia in limited-resource settings; and more. - Provides in-depth clinical reviews of Waldenström macroglobulinemia, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown︎, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue will include: Chronic Lymphocytic Leukemia: Do We Know the Cell of Origin Yet?; Significance of BCR Stereotypy; Prognostic and Predictive Implications of Cytogenetics and Genomics; Role of Epigenetics in Chronic Lymphocytic Leukemia; Genomics of Resistance to Targeted Therapies; First Line Therapy for Chronic Lymphocytic Leukemia; The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia Therapy; BTK Inhibitors; Minimal Residual Disease; Should Undetectable MRD Be the Goal of Chronic Lymphocytic Leukemia Therapy?; Management of Chronic Lymphocytic Leukemia after Progression on BTK Inhibitors; Role of PI3K Inhibitors in Chronic Lymphocytic Leukemia; Can We Restore the Immunodeficiency of Chronic Lymphocytic Leukemia?; and Immune Therapy for Chronic Lymphocytic Leukemia

In this issue of Hematology/Oncology Clinics, guest editor Dr. David E. Fisher brings his considerable expertise to the topic of Cutaneous Oncology. Top experts first provide information on skin structure, function, and immunology, then offer overviews of the therapeutic state of the art for both melanoma and non-melanoma skin cancers. Discussions focus on unique clinical challenges and biological breakthroughs which have come to light in recent studies of cutaneous malignancies. - Contains 16 relevant, practice-oriented topics including high risk non-melanoma skin cancers; progress in immune checkpoints for melanoma therapy; targeted therapy innovations for melanoma; advances in vaccines for melanoma; microbiome and immunotherapy; Merkel cell carcinoma; and more. - Provides in-depth clinical reviews on cutaneous oncology, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. Raymond L. Comenzo, is devoted to Systemic Amyloidosis due to Monoclonal Immunoglobulins. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: The Spectrum of Monoclonal Immunoglobulin Diseases, Systemic Amyloidosis due to Clonal Plasma Cell Diseases, Systemic Amyloidosis due to Low-grade Lymphomas, The Process of Amyloid Formation due to Monoclonal Immunoglobulins, Cardiac Involvement, Renal Involvement, Liver and Gastrointestinal Involvement, Peripheral Nervous System Involvement, Options for Chemotherapy, Stem-cell Mobilization and Autologous Transplant, Monoclonal Antibody Therapies, Solid Organ Transplant, Supportive Care, Patient Voices, and Future Perspectives.